Biocon has informed about a Press Release dated June 03, 2016 titled ‘Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting’.
The above information is a part of company’s filings submitted to BSE.